Deborah Rathjen CEO & Managing Director Safe Harbor Statement - PowerPoint PPT Presentation

Creating and developing innovative therapies Deborah Rathjen CEO & Managing Director

Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ development candidates BNC105, BNC210 (IW-2143), BNC101(ET101) and BNC375, its licensing agreements with Ironwood Pharmaceuticals and Merck & Co, its acquisition of Eclipse Therapeutics, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. 2

Bionomics Snapshot 6 MONTH SHARE PRI CE PERFORMANCE KEY STATI STI CS ( July 2 0 1 3 ) ASX code BNO Share price ( 2 6 / 7 / 1 3 ) A$ 0 .4 0 5 2 w eek high A$ 0 .4 5 5 5 2 w eek low A$ 0 .2 4 5 Shares on issue 4 1 1 .1 M  A$ 1 6 4 M Market capitalisation Cash 3 0 / 6 / 1 3 A$ 2 2 .5 M BOARD MANAGEMENT Graem e Kaufm an Chairm an Deborah Rathjen CEO & MD Deborah Rathjen CEO & MD Trevor Tappenden Non-exec Director José I glesias CMO Errol DeSouza Non-exec Director Melanie Young CFO & Com pany Secretary Jonathan Lim Non-exec Director 3

Bionomics Investment Highlights Emerging biotech with global operations in Australia (ASX:BNO), Europe and the  United States World class discovery and development capabilities targeting multi-billion dollar  market opportunities in solid tumour oncology, CNS, and immune diseases Broad and deep portfolio of clinical and preclinical drug candidates supported by  proprietary technology platforms: BNC1 0 5 solid tumour targeting agent in Phase II trials for renal and ovarian cancer with key data in  early 2014 BNC2 1 0 (IW-2143) targeting anxiety and depression partnered with Ironwood Pharmaceuticals  US$345 million in upfront, research and milestone payments, plus royalties  BNC1 0 1 and other Cancer Stem Cell (CSC) targeting antibodies from the acquisition of Eclipse  Therapeutics; BNC1 0 1 entering clinic in 2014 Nav1 .7 program targeting chronic and neuropathic pain partnered with Merck & Co (MSD)  US$172 million in option exercise fees, development and regulatory milestone payments, plus  royalties Partnerable Kv1 .3 program and BNC3 7 5 drug candidate anticipated to generate additional value  inflection points in CY2013 Strategy to partner our compounds at key value points to crystallise value, improve rate of success and manage risk 4

Bionomics Business Model Partnering is key to managing execution risk, validating our compounds and ensuring our compounds reach their markets Drug Drug Partnering Discovery Development Targeted clinical Platform for • Lay off risk with • • trials delivering new drug experienced candidates partners • Propagates pipeline • Generate revenue with multiple shots streams to support on goal discovery programs 5

Drug Candidate Portfolio Leverages Core Strengths CORE PRE- LI CENSEE/ DRUG CANDI DATE/ PROGRAM DI SCOVERY PHASE I PHASE I I CLI NI CAL PARTNER STRENGTHS BNC1 0 5 – Solid Tumours, renal, ovarian, mesothelioma BNC1 0 1 – Cancer stem cells, Solid Tumours, colon, breast, pancreatic CANCER BNC1 0 2 – Cancer stem cells, Solid Tumours VEGFR3 – Solid Tumours, melanoma, breast RET – lung and thyroid Cancers BNC2 1 0 ( I W -2 1 4 3 ) – Anxiety/Depression CENTRAL BNC3 7 5 – Cognitive impairment, Alzheimer's Disease, ADHD, schizophrenia NERVOUS SYSTEM GABA-A – Epilepsy NaV1 .7 - Pain I MMUNE Kv1 .3 –Psoriasis, Multiple Sclerosis, Rheumatoid Arthritis DI SEASE Targeted licensing point 6

Nav 1.7: $172M Pain Partnership with Merck & Co  Deal further validates ionX & MultiCore drug discovery platforms  Value creation through strategic partnering business model  Future success-based revenue streams & royalties secured Option and license agreement with Merck & Co  COMMERCI AL US$ 1 7 2 m in option exercise fees, development/regulatory milestone  ELEMENTS payments, plus royalties THERAPEUTI C Treatment of chronic pain, including neuropathic pain  AREA Pain Market totalled US$22 billion in sales in 2010  Neuropathic pain segment of market expected to grow from US$2.4  billion in 2010 to US$3.6 billion by 2020 MARKET SI ZE Current medications have limited effectiveness:  & estimated only 1 in 4 patients with neuropathic pain achieve  POSI TI ONI NG >50% reduction in pain levels side-effects include drowziness, somnolence and dizziness  Nav1.7 as a target has been validated through genetic studies  VALI DATI ON 7

BNC210 (IW-2143): A next generation compound with potential in the treatment of anxiety and depression TREATMENT Anxiety and Depression Modulates novel pathway, to promote anti-anxiety activity and neurite  MODE OF outgrowth in vitro. ACTI ON Four Phase I trials completed, including a trial assessing panic attack  symptoms: 59 subjects enrolled in double-blinded placebo controlled trial;15  subjects classified as having a panic attack upon CCK-4 administration Statistically significant decrease in both number & intensity of  symptoms (p<0.05) CLI NI CAL BNC210 treated subjects returned to normal emotional status within  10 minutes, compared to 60 minutes on placebo This trend correlated with the statistically significant reduction in  panic symptoms by BNC210 BNC210 has been administered to 108 healthy subjects to date with  excellent safety profile  BNC210-related changes in human brain activity indicative of efficacy  Reduced panic symptoms BENEFI TS  No evidence of sedation or addiction to date  Anxiety – global sales of US$5-7bn annually  Depression – global sales  US$11bn MARKETS  Partnered with Ironwood (NASDAQ:IRWD) US$345 million in upfront, research and milestone payments, plus royalties 8

BNC210 (IW-2143): Fewer side-effects expected to be a key product differentiator COMPETI TI VE ADVANTAGES OF BNC2 1 0 * NO ONCE-A- NO NO MEMORY FAST NO DRUG/ DRUG DRUG W I THDRAW AL DAY SEDATI ON I MPAI RMENT ACTI NG I NTERACTI ONS SYNDROME DOSI NG       BNC2 1 0       VALI UM       PROZAC       BUSPAR * Based on preclinical data and results of Phase I trial comparing BNC210 with Lorazepam 9

BNC375: More than Alzheimer’s Disease  7 NAChR receptor activation improves attention, working memory  and recognition memory Following late-stage development failures by drugs targeting β -  amyloid (Lilly, Pfizer, J&J),  7 NAChR approaches have come to the forefront; Pharma hungry for AD drugs Market opportunity for drugs modulating  7 NAChR activity includes  many neurodegenerative and psychiatric disorders: Alzheimer’s Disease (AD), Parkinson’s Disease, Schizophrenia, ADHD and  mood and anxiety disorders Prevalence Estim ated Global sales Alzheimer’s 9.7 Million $10.2 Billion Disease (2012) Cognitive 3.4 Million No approved Dysfunction in products Schizophrenia ADHD 44.9 Million $4.9 Billion Parkinson’s 7.0 Million $3.5 Billion Disease 10

BNC375: Competitive advantages* Bionom ics Com peting Characteristics BNC3 7 5 Agents+ Potent   Rapid onset of action   Potentiates endogenous receptor   ligand Preserve the normal signalling   patterns of the receptor Do not cause receptor   desensitization No potential for development of   tolerance Selectivity over other nicotinic   receptors *Based on data from preclinical animal studies +Published information and Bionomics’ in-house data 11